Thursday - June 19, 2025
BRANFORD, Conn. / Feb 13, 2025 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, and several distinguished researchers will highlight advances in Next-Generation Protein Sequencing™ (NGPS™) at the US Human Proteome Organization’s 2025 conference in Philadelphia, Pennsylvania through a panel discussion and multiple poster presentations.
Sponsored Panel Discussion: Breaking Boundaries in Proteomics
Quantum-Si is sponsoring and moderating the panel event “Breaking Boundaries: How Next-Generation Protein Sequencing™ is Shaping the Future of Proteomics” on February 25 from 12:30-1:30 PM ET. The session will provide an overview of the latest research leveraging Quantum-Si’s Platinum® Pro benchtop instrument, including a pioneering protein barcoding kit for sample multiplexing and a new library preparation solution for lower sample input.
Following the presentation, Dr. Benjamin Garcia (Washington University in St. Louis), Dr. Stephanie Cologna (University of Illinois Chicago), and Dr. John Prensner (University of Michigan) will engage in a discussion on the transformative impact of NGPS on proteomics, its role in overcoming existing challenges, and its integration with complementary technologies.
Scientific Posters Highlighting NGPS Innovation
Protein Sequencing with Single Amino Acid Resolution Discerns Myopathy-linked Regions in Tropomyosin Peptidoforms
Reducing Protein Input for Next-Generation Protein Sequencing on the Platinum Instrument
Accurate Measurement of Peptide Variant Mixtures with Next-Generation Protein Sequencing
Protein Barcoding and Next-Generation Protein Sequencing for Multiplexed Protein Selection, Analysis and Tracking
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum® line of instruments enables Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.
Last Trade: | US$1.75 |
Daily Change: | 0.07 4.17 |
Daily Volume: | 5,593,197 |
Market Cap: | US$242.200M |
June 17, 2025 June 10, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load